紧急程度中等
-极为严肃
- Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide. IARC CancerBase No 11, 2013.
- Lowe KA, Chia VM, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013;130:10714.
- Maringe C, Walters S, Butler J, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol2012;127:7582.
- Sundar S. Benign and malignant ovarian masses. In: Obstetrics and gynaecology: an evidencebased text for MRCOG. 2010, Hodder.
- Perets R, Wyant GA, Muto KW, et al. Transformation of the fallopian tube secretory epithelium leads to highgrade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:75165.
- Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutationpositive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:265463.
- Royal College of Obstetricians and Gynaecologists. Management of women with a genetic predisposition to gynaecological cancers. Scientific Impact paper No 48, Feb 2015.
- Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the AshkenaziJewish community: a randomized controlled trial. J Natl Cancer Inst 2015;107:379.
- Manchanda R, Legood R, Burnell M, et al. Costeffectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family historybased testing. J Natl Cancer Inst 2015;107:380.
- CandidodosReis FJ, Song H, Goode EL, et al. Germline mutation in BRCA1 or BRCA2 and tenyear survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2015;21:6527
© TeckelMedical 2026
